Literature DB >> 22700442

Serum autotaxin is not a useful biomarker for ovarian cancer.

Kazuhiro Nakamura1, Koji Igarashi, Ryunosuke Ohkawa, Hiromitsu Yokota, Akiko Masuda, Shunsuke Nakagawa, Tetsu Yano, Hitoshi Ikeda, Junken Aoki, Yutaka Yatomi.   

Abstract

Autotaxin (ATX) is a glycoprotein that was first identified in the conditioned medium of human melanoma cells as an autocrine motility factor. It possesses lysophospholipase D activity, producing the bioactive lipid mediator lysophosphatidic acid (LPA) from lysophosphatidylcholine. Enhanced expression of ATX mRNA has been reported in various cancer cells and tissues, and it has been speculated that ATX overexpression in cancer cells may be associated with aberrant LPA production. LPA and ATX have been implicated in cancer progression and metastasis, and ovarian cancer is a representative example. In the present study, we measured the serum ATX antigen levels in patients with ovarian cancer and evaluated the usefulness of this parameter for clinical laboratory testing. The serum ATX antigen levels were not increased in ovarian cancer patients as compared with the levels in healthy subjects, and the serum ATX may not be useful as a biomarker for ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22700442     DOI: 10.1007/s11745-012-3691-0

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  18 in total

1.  Measurement of lysophospholipase D/autotaxin activity in human serum samples.

Authors:  Kazuhiro Nakamura; Ryunosuke Ohkawa; Shigeo Okubo; Minoru Tozuka; Mitsumasa Okada; Shinya Aoki; Junken Aoki; Hiroyuki Arai; Hitoshi Ikeda; Yutaka Yatomi
Journal:  Clin Biochem       Date:  2006-10-19       Impact factor: 3.281

2.  GPR92 as a new G12/13- and Gq-coupled lysophosphatidic acid receptor that increases cAMP, LPA5.

Authors:  Chang-Wook Lee; Richard Rivera; Shannon Gardell; Adrienne E Dubin; Jerold Chun
Journal:  J Biol Chem       Date:  2006-06-14       Impact factor: 5.157

3.  Both plasma lysophosphatidic acid and serum autotaxin levels are increased in chronic hepatitis C.

Authors:  Naoko Watanabe; Hitoshi Ikeda; Kazuhiro Nakamura; Ryunosuke Ohkawa; Yukio Kume; Junken Aoki; Kotaro Hama; Shinichi Okudaira; Masayuki Tanaka; Tomoaki Tomiya; Mikio Yanase; Kazuaki Tejima; Takako Nishikawa; Masahiro Arai; Hiroyuki Arai; Masao Omata; Kenji Fujiwara; Yutaka Yatomi
Journal:  J Clin Gastroenterol       Date:  2007-07       Impact factor: 3.062

4.  Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers.

Authors:  Y Xu; Z Shen; D W Wiper; M Wu; R E Morton; P Elson; A W Kennedy; J Belinson; M Markman; G Casey
Journal:  JAMA       Date:  1998-08-26       Impact factor: 56.272

5.  Measurement of plasma lysophosphatidic acid concentration in healthy subjects: strong correlation with lysophospholipase D activity.

Authors:  Shigemi Hosogaya; Yutaka Yatomi; Kazuhiro Nakamura; Ryunosuke Ohkawa; Shigeo Okubo; Hiromitsu Yokota; Masato Ohta; Hirokazu Yamazaki; Toru Koike; Yukio Ozaki
Journal:  Ann Clin Biochem       Date:  2008-07       Impact factor: 2.057

6.  Validation of an autotaxin enzyme immunoassay in human serum samples and its application to hypoalbuminemia differentiation.

Authors:  Kazuhiro Nakamura; Koji Igarashi; Kazufumi Ide; Ryunosuke Ohkawa; Shigeo Okubo; Hiromitsu Yokota; Akiko Masuda; Noriko Oshima; Takumi Takeuchi; Masaomi Nangaku; Shinichi Okudaira; Hiroyuki Arai; Hitoshi Ikeda; Junken Aoki; Yutaka Yatomi
Journal:  Clin Chim Acta       Date:  2007-10-11       Impact factor: 3.786

7.  Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.

Authors:  Malgorzata M Ptaszynska; Michael L Pendrak; Russell W Bandle; Mary L Stracke; David D Roberts
Journal:  Mol Cancer Res       Date:  2008-03       Impact factor: 5.852

8.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

9.  Serum autotaxin measurement in haematological malignancies: a promising marker for follicular lymphoma.

Authors:  Akiko Masuda; Kazuhiro Nakamura; Koji Izutsu; Koji Igarashi; Ryunosuke Ohkawa; Masahiro Jona; Katsumi Higashi; Hiromitsu Yokota; Shinichi Okudaira; Tatsuya Kishimoto; Takuro Watanabe; Yukako Koike; Hitoshi Ikeda; Yasushi Kozai; Mineo Kurokawa; Junken Aoki; Yutaka Yatomi
Journal:  Br J Haematol       Date:  2008-08-15       Impact factor: 6.998

10.  Autotaxin delays apoptosis induced by carboplatin in ovarian cancer cells.

Authors:  Susanne Vidot; James Witham; Roshan Agarwal; Sebastian Greenhough; Harnoor S Bamrah; Gabor J Tigyi; Stanley B Kaye; Alan Richardson
Journal:  Cell Signal       Date:  2010-01-25       Impact factor: 4.315

View more
  7 in total

1.  Plasma levels of lysophosphatidic acid in ovarian cancer versus controls: a meta-analysis.

Authors:  Yi-Yang Li; Wen-Chao Zhang; Jia-Ling Zhang; Chang-Jun Zheng; He Zhu; Hui-Mei Yu; Li-Mei Fan
Journal:  Lipids Health Dis       Date:  2015-07-15       Impact factor: 3.876

2.  A new spontaneously transformed syngeneic model of high-grade serous ovarian cancer with a tumor-initiating cell population.

Authors:  Curtis W McCloskey; Reuben L Goldberg; Lauren E Carter; Lisa F Gamwell; Ensaf M Al-Hujaily; Olga Collins; Elizabeth A Macdonald; Kenneth Garson; Manijeh Daneshmand; Euridice Carmona; Barbara C Vanderhyden
Journal:  Front Oncol       Date:  2014-03-18       Impact factor: 6.244

Review 3.  Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2018-07-09       Impact factor: 6.639

4.  Aberrant lipid metabolism: an emerging diagnostic and therapeutic target in ovarian cancer.

Authors:  Carmen E Pyragius; Maria Fuller; Carmela Ricciardelli; Martin K Oehler
Journal:  Int J Mol Sci       Date:  2013-04-10       Impact factor: 5.923

5.  Non-invasive imaging of tumors by monitoring autotaxin activity using an enzyme-activated near-infrared fluorogenic substrate.

Authors:  Damian Madan; Colin G Ferguson; Won Yong Lee; Glenn D Prestwich; Charles A Testa
Journal:  PLoS One       Date:  2013-11-20       Impact factor: 3.240

6.  Reduced levels of N'-methyl-2-pyridone-5-carboxamide and lysophosphatidylcholine 16:0 in the serum of patients with intrahepatic cholangiocarcinoma, and the correlation with recurrence-free survival.

Authors:  Kyung-Hee Kim; Jungnam Joo; Boram Park; Sang-Jae Park; Woo Jin Lee; Sung-Sik Han; Tae Hyun Kim; Eun Kyung Hong; Sang Myung Woo; Byong Chul Yoo
Journal:  Oncotarget       Date:  2017-11-22

Review 7.  Targeting Lysophosphatidic Acid in Cancer: The Issues in Moving from Bench to Bedside.

Authors:  Yan Xu
Journal:  Cancers (Basel)       Date:  2019-10-10       Impact factor: 6.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.